- The failed proposed recommendations SCCR/30
- Summary by the Chair, of SCCR 30
- SCCR 30: Resale right proposal on the table?
- KEI intervention on education exceptions in SCCR 30
- SCCR30: United States- Preservation - Copyright limitations and exceptions for libraries and archives
- KEI intervention on preservation exceptions at WIPO SCCR 30
- Chairman's non-paper on copyright exceptions for libraries, archives
- SCCR30 (Day 4): Discussion heats up on discussions on copyright limitations and exceptions for libraries and archives
- Iran’s Statement on the limitations and exceptions at WIPO SCCR 30
- SCCR 30 End of Session on the Broadcasters’ Treaty: Snail pace to -almost- reach consensus
KEI comments to DHHS on WHA agenda 17.4, the Consultative Expert Working Group on Research and DevelopmentSubmitted by James Love on 8. May 2015 - 9:47
Re: 17.4 Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination Document A68/34
My name is James Love, from Knowledge Ecology International. I wanted to discuss the negotiations on new approaches to funding medical R&D.
I will begin with the much delayed discussions about a WHO R&D treaty, which are supposed to resume in 2016.
We have suggestions for some changes in the discussion, to move things forward.
On Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here:
On Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here: http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_1-en.pdf
WHO Expert Committtee adds trastuzumab, imatinib, daclatasvir, sofosbuvir, bedaquiline and delaminid to EMLSubmitted by thiru on 8. May 2015 - 2:34
On Friday, 8 May 2015, the World Health Organization (WHO) unveiled its 19th WHO Model of Essential Medicines (April 2015).
With respect to cancer drugs (Section 8.2, Cytoxic and Adjuvant Medicines), the Executive Summary noted that the Committee added 16 new medicines.
WHO donors in 2014 (US, Gates Foundation, UK, GAVI and Canada): Setting the agenda for global public health?Submitted by thiru on 7. May 2015 - 4:46
In preparation for the 68th World Health Assembly, to be convened in Geneva from 18 May 2015 to 26 May 2015, the World Health Organization (WHO) prepared a document (A68/INF./1, 1 May 2015), entitled "Annex to the Financial Report for the year ended 31 December 2014, Voluntary contributions by fund and by contributor).
On May 5, 2015, KEI sent a letter to the USPTO regarding the implementation of the Beijing Treaty on Audiovisual Performances. The letter focuses on concerns that KEI and others have expressed that a treaty implementation by amendment of 17 U.S. Code § 1101, regarding the "Unauthorized fixation and trafficking in sound recordings and music videos," creates problems, because the statute involves a right that is perpetual and not subject to normal copyright exceptions.
NIH refuses to give information about principals in company seeking exclusive license to HCV patentsSubmitted by KEI Staff on 5. May 2015 - 10:24
The NIH provided these responses to four questions about the HCV drug patent license it is considering.
Every year USTR issues a list of countries targeted to be subjected to trade pressures over their policies on intellectual property rights. This year's list was published on April 30, 2015. KEI has a copy of every version of the Special 301 list here: http://www.keionline.org/ustr/special301
USTR describes the list as follows:
The Special 301 Process
Today, KEI hosted the first talk in a series of seminars on drug pricing. The seminar, conducted via video conference, focused on the Canadian approach to drug pricing. Each seminar in the series is intended to contribute to the discussion on drug pricing and how we can improve affordability and access to medicines. Paul Grootendorst began with a presentation (the slides are available here), before opening up the discussion to questions from those participating in the video conference.
Yesterday, under intense pressure from the powerful pharmaceutical industry lobby, California Assembly Member Dan Chiu withheld bill AB 463, the Pharmaceutical Cost Transparency Act of 2015. A vote on the bill had already been postponed for a week in order to allow Assembly Member Chiu more time to address various concerns raised by colleagues in the Health Committee.
Kassy Perry, speaking on behalf of ?, opposing AB 463, on transparency of drug R&D costs and subsidiesSubmitted by KEI Staff on 29. April 2015 - 11:41
During the debate of California bill AB 463, on the Pharmaceutical Cost Transparency Act of 2015, Kassy Perry was using Twitter to attack the bill, posting links to and repeating pharmaceutical industry talking points. Who is Kassy Perry? A founder of Perry Communications, a Sacramento public relations and lobbying firm. This is her Twitter profile:
Public Citizen, National Physicians Alliance, Other Civil Society Groups Write Letters in Support of California AB 463Submitted by Andrew Goldman on 23. April 2015 - 8:56
In addition to the numerous groups and institutions that stood in support of AB 463 (Pharmaceutical Cost Transparency Act of 2015) at the California Assembly Health Committee hearing on April 21st, six civil society groups that we are aware of have submitted letters or statements in support of the bill.
In alphabetical order, these include:
1. American Medical Students Association (AMSA)
2. National Council of Asian Pacific Islander Physicians (NCAPIP)
3. National Physicians Alliance (NPA)
4. Public Citizen
5. Universities Allied for Essential Medicines (UAEM)
KEI Notes on California Assembly Health Committee Markup on AB 463 Pharmaceutical Cost Transparency Act of 2015Submitted by Andrew Goldman on 22. April 2015 - 7:46
Yesterday (April 21,2015) the California Assembly held a Health Committee hearing to discuss various bills being offered, including Assembly Member Dan Chiu's AB 463, titled the Pharmaceutical Cost Transparency Act of 2015.
AB 463 calls for the pharmaceutical industry to annually report its costs for developing and manufacturing a drug (for any course of treatment over $10k). The bill seeks to provide audited information on R&D costs, a topic for which the industry often makes unsupported and exaggerated claims.
KEI Seminars on Drug Pricing: 30 April 2015, Prof. Paul Grootendorst on the Canadian approach to drug pricingSubmitted by Claire Cassedy on 21. April 2015 - 15:02
On Thursday, 30 April 2015, KEI will host the first talk in a series of seminars on drug pricing. The seminars will take place via video conference (hosted by KEI), and participation is welcome either by attending the presentation at KEI’s Washington, DC offices, or to the extent we are able, joining the digital conference.
Yesterday, Politico published this story:
Leaked digital single market’s ‘evidence file’ reveals Commission’s ambitions. Documents show policy came before evidence for cybersecurity measures.
By ZOYA SHEFTALOVICH 20/4/15, 1:29 PM CET Updated 21/4/15, 11:33 AM CET